The latest price target for Spyre Therapeutics (NASDAQ:SYRE) was reported by Baird on November 13, 2024. The analyst firm set a price target for $65.00 expecting SYRE to rise to within 12 months (a possible 128.63% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Spyre Therapeutics (NASDAQ:SYRE) was provided by Baird, and Spyre Therapeutics maintained their outperform rating.

The last upgrade for Spyre Therapeutics Inc happened on March 1, 2024 when Wells Fargo raised their price target to $35. Wells Fargo previously had an equal-weight for Spyre Therapeutics Inc.

There is no last downgrade for Spyre Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spyre Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spyre Therapeutics was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Spyre Therapeutics (SYRE) rating was a maintained with a price target of $50.00 to $65.00. The current price Spyre Therapeutics (SYRE) is trading at is $28.43, which is out of the analyst’s predicted range.